Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 85%
filed 2026-05-21
Item 8.01
VisionWave issued 475,492 newly issued shares of common stock to T3 Defense Inc. in a private placement exempt from registration under Section 4(a)(2) of the Securities Act. The shares were issued as restricted securities with a customary restrictive legend and contractual transfer restrictions. This is a dilutive equity issuance that would materially affect existing shareholders' ownership percentages and is a key indicator of capital-raising activity at a small-cap issuer.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
Monroe Capital Income Plus Corp conducted an unregistered private placement of 1,174,995 shares of common stock at $9.77 per share, raising approximately $11.48 million in aggregate proceeds pursuant to subscription agreements and exempt under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
Perella Weinberg Partners issued 1,908,084 shares of Class A common stock on May 18, 2026, in exchange for partnership units and Class B shares held by limited partners. The transaction was structured as an unregistered exchange under Section 4(a)(2) of the Securities Act, involving a material issuance of equity securities that dilutes existing shareholders. This is a classic dilutive issuance disclosure under Item 3.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
Blackstone Private Credit Fund completed an unregistered private placement of 2,171,851 Class I common shares for $52.3 million, conducted pursuant to Section 4(a)(2) and Regulation S exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
Barings Private Credit Corp completed an unregistered sale of 715,267.588 shares of common stock for approximately $14.3 million pursuant to subscription agreements with investors, exempt under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-05-21
Item 8.01
D-Wave has signed a Letter of Intent to receive $100 million in CHIPS Act funding, contingent on issuing $100 million in common stock shares to the U.S. Department of Commerce. The filing explicitly identifies "the risk of dilution to existing stockholders from the Company's issuance of the Shares to the Department," confirming the dilutive nature of this equity issuance. While the transaction is subject to execution of definitive documents, the LOI represents a material commitment to issue equity for funding.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
TPG Private Equity Opportunities, L.P. sold unregistered limited partnership units totaling $78.8 million on May 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions. This private placement represents a dilutive issuance of material size affecting investor assessment of the registrant's capital structure and ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 3.02
Stone Point Credit Income Fund disclosed an unregistered sale of 110,889.543 common shares at net asset value of $24.7599 for aggregate proceeds of $2,745,614, conducted pursuant to Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement by a fund raising capital from accredited investors without public registration, directly matching the dilutive_issuance taxonomy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 1.01
Golden Minerals entered into a Subscription Agreement for a private placement of 3,740,000 common shares at $0.2290 per share, raising approximately $856,463 in gross proceeds under Section 4(a)(2) and Regulation D/S without registration. This unregistered equity issuance materially dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 1.01
Annovis Bio entered into an Underwriting Agreement on May 20, 2026 to issue 7,895,000 shares of common stock and 7,105,500 warrants in a public offering expected to raise approximately $15 million in gross proceeds, with net proceeds to be used for clinical development and working capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 1.01
NanoViricides entered into a Securities Purchase Agreement on May 15, 2026, for a registered direct offering of 1,133,334 shares of common stock at $1.50 per share, along with pre-funded warrants and common warrants, generating approximately $2.0 million in gross proceeds. The offering closed on May 18, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 8.01
CareTrust REIT completed a registered public offering of 12.5 million shares of common stock at $40.225 per share on May 20, 2026, with an additional 1.875 million shares available under an underwriter option. The offering was conducted through a forward sale structure with Wells Fargo and JPMorgan Chase as forward purchasers. This is a material dilutive equity issuance that increases the company's share count and raises capital, disclosed pursuant to an effective S-3 shelf registration statement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 1.01
Cenntro entered into securities purchase agreements for a private placement of 1,000,000 shares of common stock at $3.93 per share for approximately $3.93 million in gross proceeds. The issuance qualifies under Nasdaq Listing Rule 5635(d) as a 20% or greater dilution of outstanding common stock, exempt under Section 4(a)(2) and Regulation S with transfer restrictions and legend requirements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 8.01
Akamai announced the pricing of $3 billion in aggregate principal amount of convertible senior notes ($1.5 billion due 2030 and $1.5 billion due 2032) in a private offering to qualified institutional buyers. This is a material dilutive issuance of convertible debt securities that will likely result in equity dilution upon conversion, consistent with Item 3.02 disclosure requirements and the dilutive_issuance event type.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 3.02
AB Private Lending Fund completed an unregistered sale of 4,045 Class I common shares of beneficial interest to feeder vehicles under Section 4(a)(2) and Regulation S exemptions. This private placement raises capital while diluting existing shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 3.02
The filing discloses an unregistered sale of 211,900 Shares in a private placement to accredited investors under Rule 506(c) of Regulation D, representing an aggregate of 4,038.87 TAO worth $1,149,569. This is a classic dilutive issuance exempt from registration requirements, with Grayscale Securities acting as Authorized Participant and potential underwriter. The disclosure explicitly references Item 3.02 (Unregistered Sales of Equity Securities) and notes that periodic share creation may constitute ongoing distributions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 3.02
The Company disclosed the sale of 30,481 Class D Common Shares for $840,000 under a continuous private placement offering of up to $2.165 billion in unregistered equity securities pursuant to Section 4(a)(2) and Regulation D Rule 506(c). This is a classic dilutive issuance of unregistered equity securities, and the forward-looking statements explicitly warn that "future sales or issuances of our Common Shares or other securities convertible into our Common Shares, or the perception thereof, could cause the value of our Common Shares to decline and could result in dilution."
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-20
The filing discloses entry into a sales agreement with Aegis Capital Corp. for an "at the market" offering program under which the Company may sell up to $60.0 million of common stock shares. This is a dilutive equity issuance under Item 1.01, structured as an ATM offering pursuant to Rule 415(a)(4) under the Securities Act of 1933. The magnitude ($60 million) and nature of the offering (unregistered equity sales to raise capital) are material to investors' assessment of share dilution and the registrant's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 3.02 discloses an unregistered sale of equity securities completed on May 19, 2026, consisting of bonds and 16 warrants yielding approximately $56 million in gross proceeds. The warrants entitle holders to purchase 2,603,936 shares of common stock at an exercise price of NIS 39.8 (approximately $13.69), creating significant dilution potential. This is a classic dilutive issuance under Regulation S, with the underlying shares to be registered on Form S-3.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-20
Item 8.01
AE Industrial Partners converted 46,505.13 shares of Convertible Preferred Stock into 15,247,586 shares of common stock, eliminating all remaining Convertible Preferred Stock outstanding and materially increasing the common share count and diluting existing shareholders' ownership percentages.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 8.01
Rocket Lab entered into an equity distribution agreement on May 20, 2026, authorizing the issuance and sale of up to $3 billion in common stock through multiple sales agents and forward sale mechanisms. This is a material dilutive issuance that would significantly affect shareholder equity and voting power. The agreement includes both direct share sales and forward sale agreements (Initially Priced and Collared Forward Transactions), all of which contemplate the eventual issuance of common stock to raise capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 3.02
The filing discloses an unregistered sale of approximately 580,074 shares of common stock for $9.4 million pursuant to subscription agreements and Section 4(a)(2)/Regulation D exemptions. This is a classic private placement equity issuance that dilutes existing shareholders and raises capital, fitting the dilutive_issuance category. The material amount ($9.4 million) and significant share count make this material to investors assessing ownership and capitalization.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 1.01
Capital Southwest Corporation amended its at-the-market (ATM) offering program on May 19, 2026, increasing the maximum aggregate offering amount from $1.0 billion to $2.0 billion through sixth amendments to equity distribution agreements with four sales agents (Jefferies, Raymond James, Citizens Capital Markets, and B. Riley). This is a material dilutive issuance under Item 1.01, as it substantially expands the company's capacity to issue common stock and would materially affect shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 8.01
Farmer Mac completed an issuance of 4,000,000 shares of preferred stock in an exempt public offering on May 19, 2026. While this is a preferred stock issuance rather than common equity, it represents a material capital raise that dilutes existing shareholders' ownership and is typically disclosed under Item 3.02 (Unregistered Sales) or Item 8.01 (Other Events). The issuance of 4 million shares of preferred stock with a stated dividend rate (6.875%) is material to investors assessing the company's capital structure and financing activities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 1.01
InMed Pharmaceuticals amended preferred investment options with Armistice Capital, reducing the exercise price from $16.60 to $0.80 per share on 278,761 common shares. This substantial downward repricing converts out-of-the-money warrants into deeply in-the-money instruments, significantly increasing the likelihood of exercise and dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-05-19
Item 5.02
The Board approved debt-to-equity conversion agreements with four creditors (including the CEO and VP Administration) whereby the Company will issue 1,509,710 common shares in aggregate to settle approximately C$1.24 million in deferred management fees, subject to regulatory approvals and shareholder vote.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
Kimbell issued 6,929,000 OpCo Common Units and Class B Units as part of the acquisition consideration, representing an unregistered equity issuance under Section 4(a)(2) exemption that materially dilutes existing ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
In connection with the IPO closing, the Company issued warrants to purchase 71,875 shares of Common Stock to Lucid as underwriting compensation, relying on the Section 4(a)(2) exemption from registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
The filing discloses unregistered issuances of equity securities totaling 310,575 shares upon conversion of a convertible note, relying on Section 4(a)(2) exemption. This represents a dilutive capital event where the company issued approximately 10.3% of its outstanding shares (310,575 of 3,028,362 shares) to satisfy debt obligations, which is material to investors assessing ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 1.01
The Company entered into an underwriting agreement on May 18, 2026, to conduct an underwritten public offering of 3,581,000 shares of Class A common stock plus pre-funded warrants and multiple series of warrants, with net proceeds of approximately $8.9 million. Additionally, a concurrent registered direct offering to directors and officers for 71,607 shares was executed. These are registered equity issuances that will dilute existing shareholders and raise capital, fitting the dilutive_issuance category. The materiality is clear given the substantial number of shares being issued and the capital raised.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 8.01
The Company disclosed a private offering of Convertible Senior Notes due 2032 to qualified institutional buyers pursuant to Rule 144A. Convertible notes are dilutive securities that may result in issuance of Class A common stock upon conversion, making this a dilutive issuance material to investors assessing capital structure and potential equity dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-05-19
Item 8.01
The Company converted 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42,839,103 shares of common stock on May 15, 2026, resulting in a substantial increase in common share count (approximately 1,000x conversion ratio). This mandatory conversion of preferred stock into common stock is a dilutive issuance that materially increases the equity base and would affect a reasonable investor's assessment of ownership dilution and voting power, even though the conversion was contractually mandated under the Certificate of Designation.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
Apollo Debt Solutions BDC sold 384,867 unregistered Class I Common Shares for $9.2 million to feeder vehicles, relying on Section 4(a)(2) and Regulation S exemptions. This private placement of equity securities materially affects shareholder ownership and capitalization.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 8.01
Blackstone Digital Infrastructure Trust completed its initial public offering of 87.5 million shares at $20.00 per share on May 15, 2026, with underwriters exercising a full 30-day option for additional shares, resulting in gross proceeds of $2.0 billion.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-05-19
Item 3.02
Sabre issued $150 million of exchangeable senior notes convertible into common stock at an initial exchange price of approximately $2.24 per share in a private placement relying on Section 4(a)(2) exemption. The exchangeable notes create significant dilution potential of 67–87 million shares upon exchange, with net proceeds used to repurchase $100 million of existing exchangeable notes and retire the remaining $50 million, representing a material capital structure transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 80%
filed 2026-05-19
Item 1.01
EagleRock Land, LLC completed a registered public offering of 17.3 million Class A shares at $18.50 per share on May 13, 2026, with an additional 2.595 million shares issued via an exercised option, generating approximately $333.1 million in net proceeds. The offering also involved unregistered sales of equity securities under Section 4(a)(2) exemption through warrant exercise agreements and merger transactions resulting in issuance of Class A shares.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
The Company issued unregistered equity securities to settle material obligations: shares to ACM under Section 4(a)(2) and Rule 506 of Regulation D in satisfaction of a $6M judgment, and 39M shares to Reimer Plaintiffs under Section 3(a)(10) in settlement of litigation, capped at $2M value.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 1.01
GeoVax Labs entered into a securities purchase agreement on May 18, 2026 for an unregistered private placement of pre-funded warrants and common warrants to purchase up to 6,081,081 shares of common stock, raising approximately $2.7 million in net proceeds under Section 4(a)(2) and Regulation D exemptions. The offering was announced via press release and will substantially increase share count upon warrant exercise, materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 2.03
Leviston converted $4 million of principal under a convertible note into 2,500,000 shares of Common Stock between May 12-18, 2026. This is a dilutive equity issuance resulting from debt conversion, which materially increases share count and dilutes existing shareholders. The conversion of a substantial debt obligation into equity is a material capital structure event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
Ares Strategic Income Fund sold 1,934,637 Class I common shares for $52.1 million during May 2026 in an unregistered offering exempt under Section 4(a)(2) and Regulation S, representing a material capital raise that increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
DATA I/O CORP completed an unregistered sale of equity securities, representing a dilutive issuance to existing shareholders and signaling capital-raising activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 1.01
iPower Inc. completed an Additional Optional Closing on May 19, 2026, issuing $3,000,000 principal amount of Series A senior secured convertible notes to an institutional investor under Regulation D, receiving approximately $2,820,000 in gross proceeds with a fixed conversion price of $1.03.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-05-19
Item 1.01
Sunshine Biopharma entered into a placement agent agreement for a public offering of 11.16 million Common Units and 840,000 Pre-Funded Units, generating approximately $6 million in gross proceeds, with highly dilutive pre-funded warrants exercisable at $0.00001 and Series C warrants exercisable at $0.50.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
Blue Owl Real Estate Net Lease Trust sold 3,452,243 shares of Class I common shares for approximately $36.8 million in an unregistered offering exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
Ares Core Infrastructure Fund sold 28.76 million Common Shares across four classes for an aggregate purchase price of $715.5 million in an unregistered offering exempt under Section 4(a)(2) and Regulation D (Rule 506(b)). This substantial capital raise represents a material dilutive issuance affecting investor assessment of share dilution and fund capitalization.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
Blue Owl Digital Infrastructure Trust sold 2,090,696 common shares across multiple classes (S, D, and I) for approximately $21.7 million in gross proceeds on May 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-18
Item 3.02
RMX Industries completed an unregistered private placement offering of 54.4 units (promissory notes and warrants) to accredited investors, generating $1.36 million in gross proceeds and resulting in dilution to existing shareholders.
View raw filing on EDGAR →